Clinical trial
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
NCT00280878 · Bayside Health, Other · Completed
Key facts
| NCT number | NCT00280878 |
|---|---|
| Title | Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma |
| Official title | A Pilot Study of Rituximab in Combination With Out-patient Based VGF/F-GIV Salvage Therapies for Relapsed/Refractory CD20+ Lymphomas |
| Lead sponsor | Bayside Health, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma (CD20+) |
| Intervention type | Drug |
| Interventions | gemcitabine, vinorelbine, ifosfamide, rituximab |
| Enrollment | 12 |
| Start date | Jan 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jan 24, 2006 |
| Last update posted | Jan 15, 2016 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: